MedTree Post: Insights & Tips for Healthcare Pros

10 Jul 2026

BCNA Builds Stronger Partnerships for First Peoples Breast Cancer Care

Leaders from the Breast Cancer Network Australia (BCNA) have visited Palm Island to hear directly from Aboriginal and Torres Strait Islander community members about their experiences with breast cancer care and to better understand how healthcare services can become more culturally responsive.

01 Jul 2026

PBS Listing Expands Access to Perjeta for Australians with Early Breast Cancer

From 1 July 2026, Perjeta (pertuzumab) is available on the Pharmaceutical Benefits Scheme (PBS) for eligible Australians with HER2-positive high-risk early breast cancer, making the treatment more affordable for thousands of patients.

25 May 2026

New Data Shines Light on Australians Living with Metastatic Breast Cancer

One year after an international pledge to improve recognition of metastatic breast cancer, Australia has achieved a major milestone with the release of the country's first national estimate of people living with the disease.

13 May 2026

Australia’s metastatic breast cancer data gains global attention at major conference

Australia’s approach to counting people living with metastatic breast cancer was highlighted at one of the world’s leading cancer conferences, held by the European Society for Medical Oncology (ESMO) in Berlin.

07 May 2026

Update on Zoladex treatment access for people with breast cancer

Breast Cancer Network Australia (BCNA) has confirmed it is seeking more information after AstraZeneca announced it will discontinue the Zoladex (goserelin) 3.6mg implant in Australia from 1 November 2026.

29 Sep 2025

Capivasertib (Truqap) Now Accessible on PBS for Metastatic Breast Cancer Patients

The Australian Government has recently listed capivasertib (Truqap) on the Pharmaceutical Benefits Scheme (PBS), providing an important new treatment option for people living with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC).